A generic drug maker hoping to sell its own version of the popular cholesterol drug Zetia has succeeded in knocking out part of Schering-Plough Corp.’s patent protection on the medication.
U.S. District Judge Jose Linares in Newark on Monday invalidated items of protection that were added when Schering obtained a reissued patent in 2002, ruling the patent should not have been reissued because Schering already had a valid and enforceable patent.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
